Core Viewpoint - Beijing Tongrentang has initiated legal proceedings against its subsidiary, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd., due to allegations of false labeling on a product marketed as "99% high-purity Antarctic krill oil" [1][2]. Group 1: Company Actions - Beijing Tongrentang has ordered its subsidiary to cease the distribution of the implicated product and is conducting a full process review and traceability investigation [1]. - The company claims that the product was marketed without authorization, violating legal standards, and has taken steps to protect consumer rights through legal action [2]. Group 2: Product Allegations - The product in question was reported to have misleading claims, including high phospholipid content, but testing revealed a phospholipid content of 0% [1]. - The Shanghai Consumer Protection Committee plans to interview the manufacturers and distributors involved to clarify the product's actual composition [2]. Group 3: Ownership Structure - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. is 51% owned by Beijing Tongrentang, with the remaining shares held by individual shareholders [4].